Kiadis Pharma NV (XAMS:KDS) Cash And Cash Equivalents : €13.66 Mil (As of Dec. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Cash And Cash Equivalents?

Kiadis Pharma NV's quarterly cash and cash equivalents declined from Dec. 2019 (€29.46 Mil) to Jun. 2020 (€19.81 Mil) but then stayed the same from Jun. 2020 (€19.81 Mil) to Dec. 2020 (€13.66 Mil).

Kiadis Pharma NV's annual cash and cash equivalents declined from Dec. 2018 (€60.31 Mil) to Dec. 2019 (€29.46 Mil) and declined from Dec. 2019 (€29.46 Mil) to Dec. 2020 (€13.66 Mil).

Kiadis Pharma NV Cash And Cash Equivalents Historical Data

The historical data trend for Kiadis Pharma NV's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Cash And Cash Equivalents Chart

Kiadis Pharma NV Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Cash And Cash Equivalents

Get a 7-Day Free Trial

14.56

29.91

60.31

29.46

13.66

Kiadis Pharma NV Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20
Cash And Cash Equivalents	Get a 7-Day Free Trial											60.31	62.67	29.46	19.81	13.66

Kiadis Pharma NV Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Kiadis Pharma NV (XAMS:KDS) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Kiadis Pharma NV Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiadis Pharma NV (XAMS:KDS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (XAMS:KDS) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP

Website

https://www.kiadis.com

Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (XAMS:KDS) Headlines

No Headlines